Granted Patent B2

US 8,735,547 · App. 13/870,781 · Granted May 27, 2014

Inventors: Gregory Alan Lazar (Indianapolis, IN); Wei Dang (Pasadena, CA); John Desjarlais (Pasadena, CA); Sher Bahadur Karki (Santa Monica, CA); Omid Vafa (Monrovia, CA); Robert Hayes (Paoli, PA); Jost Vielmetter (Altadena, CA)

Assignee: Xencor, Inc.

Abstract

Claims (8)

1. A protein comprising an Fc variant of a human IgG1 Fc polypeptide, wherein said Fc variant comprises an amino acid modification in the Fc region of said parent Fc polypeptide at position 243, wherein said protein exhibits altered binding affinity to an Fcγ receptor (FcγR) as compared to a parent polypeptide, wherein numbering is according to the EU index.

2. A protein according to claim 1 wherein said protein is an antibody.

3. A protein according to claim 1 wherein said protein comprises an engineered glycoform.

4. A protein according to claim 1 , 2 or 3 wherein said amino acid modification is selected from the group consisting of 243E, 243H, 243L, 243Q, 243R, 243W and 243Y.

5. A protein according to claim 4 wherein said amino acid modification is 243L.

6. A protein according to claim 2 wherein said antibody has specificity for a target antigen selected from the group consisting of CD19, CD20, CD22, CD30, CD33, CD40, CD40L, CD52, Her2/neu, EGFR, EpCAM, MUC1, GD3, CEA, CA 125, IgE, HLA-DR, TNFalpha, MUC18, prostate specific membrane antigen (PMSA) and VEGF.

7. A protein according to claim 6 wherein said antibody has specificity for her2/neu.

8. A protein comprising an Fc variant of a human IgG Fc polypeptide, wherein said Fc variant comprises an amino acid modification in the Fc region of said parent Fc polypeptide at position 243, wherein said amino acid modification is 243L, wherein said protein exhibits altered binding affinity to an Fcγ receptor (FcγR) as compared to a parent polypeptide, wherein numbering is according to the EU index.

Assignments (2)

Continuity (13)